Ambros Therapeutics
Tracked across 1 events · 6 articles · First seen Aug 21, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Werewolf Therapeutics and Ambros Therapeutics announced a definitive all-stock merger agreement to create a combined company focused on advancing neridronate, Ambros' late-stage treatment for Complex Regional Pain Syndrome Type 1 (CRPS-1). The combined company will…
Impact: Ambros Therapeutics is the target and the surviving brand, with its neridronate program being the core asset. The merger implies a $500 million valuation, and its stockholders will own approximately 71.7% of the combined company, positioning it for significant growth.
Aug 21, 2026 · 6 articles
100
Werewolf Therapeutics entered merger agreement Ambros TherapeuticsWerewolf Therapeutics Ambros Merger
80
Ambros Therapeutics received FDA designations United States — Food and Drug AdministrationWerewolf Therapeutics Ambros Merger
80
Ambros Therapeutics advancing Phase 3 trialWerewolf Therapeutics Ambros Merger
ERGEN INTELLIGENCE
Track Ambros Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard